News | Cardiovascular Clinical Studies | September 18, 2023

Substance Abuse in Pregnancy Doubles Cardiovascular Risk

Smidt Heart Institute investigators found the rise in illicit substance abuse in pregnancy is associated with significantly high risk of cardiovascular events, maternal mortality

Smidt Heart Institute investigators found the rise in illicit substance abuse in pregnancy is associated with significantly high risk of cardiovascular events, maternal mortality

New research led by Martha Gulati, MD, found that substances--like cocaine and opioids--carried different risks for expectant mothers. Photo by Cedars-Sinai. 


September 18, 2023 — Pregnant women with a history of substance abuse face a dramatically increased risk of death from heart attack and stroke during childbirth when compared with women without history of substance abuse, a new Smidt Heart Institute study shows. 

These findings are published in the Journal of the American College of Cardiology: Advances.   

“This telling research shows that substance use during pregnancy doubled cardiovascular events and maternal mortality during delivery,” said Martha Gulati, MD, senior and corresponding author of the study and the associate director of the Barbra Streisand Women’s Heart Center in the Department of Cardiology in the Smidt Heart Institute. “Substance abuse also doubled the risk of acute heart failure.” 

The substances studied in the research included cocaine, opioids, alcohol, amphetamine/methamphetamine, and cannabis. Each substance carried a different amount of risk on expectant mothers: 

  • Amphetamine/methamphetamine had the greatest association with the development of acute heart failure (nine times greater risk), acute heart attack (7 1/2 times greater risk), cardiac arrest (seven times greater risk) and maternal mortality (three times greater risk). These substances are known to increase heart rate and blood pressure and cause structural and electrical changes of the heart. 
  • Cocaine had the strongest association with stroke and was also found to be associated with arrhythmias, which are abnormal heart rhythms. 
  • Opioid use had the strongest association with infection of the heart valves—a disease known as endocarditis—which was not surprising given that these drugs are often injected into the bloodstream. 
  • Alcohol use was associated with the greatest risk for arrhythmias. 
  • Cannabis—the most commonly used substance—was not associated with maternal mortality. It was, however, associated with a higher risk (twofold greater risk) of heart attack. 

“Despite the widespread legalization of cannabis across the nation, many people are unfamiliar with the risks it can pose during pregnancy,” said Gulati, also the director of Preventive Cardiology in the Smidt Heart Institute and the Anita Dann Friedman Endowed Chair in Women’s Cardiovascular Medicine and Research. “Cannabis causes heart cell death and can also lead to severe cardiovascular events.” 

To decipher these results, study investigators reviewed data on delivery hospitalizations between 2004 and 2018, using the Nationwide Inpatient Sample database. A total of 60,014,368 delivery hospitalizations occurred during the time frame, with substance use complicating 955,531 deliveries, or 1.6%. 

 

Christine M. Albert, MD, MPH, is chair of the Department of Cardiology at the Smidt Heart Institute. Photo by Cedars-Sinai. 

Of the 1.6% of substance-related deliveries, women experienced conditions including heart attack, stroke, arrhythmia, endocarditis, acute cardiomyopathy, heart failure and cardiac arrest. 

Investigators say these findings underscore an important public health issue. 

“This study highlights the need for additional medical care for pregnant women with substance use,” said Christine M. Albert, MD, MPH, chair of the Department of Cardiology in the Smidt Heart Institute and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology. 

Albert also suggests that prenatal care for women with a history of substance use should include a multidisciplinary cardio-obstetrics approach with high-risk pregnancy specialists and cardiologists to help identify and minimize adverse outcomes. 

“For the wellbeing of pregnant women and their children, substance abuse needs to be considered an independent risk factor for cardiovascular events in pregnancy,” Albert said.   

For ore information: www.cedars-sinai.org 

 

Related Women's Heart Health Content: 

Diagnostic Differences in Women’s Heart Health 

VIDEO: Differences in Cardiac Complications and Presentation Between Men and Women — Interview with Cindy Grines, M.D. 

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races 

Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women 

Marked Increase in Cardiovascular Risk Factors in Women After Preeclampsia 

VIDEO: Sex Differences in Diagnosing Heart Disease in Women — Interview with Doreen DeFaria Yeh, M.D. 

VIDEO: How to Build a Successful Women’s Heart Center — Interview with Malissa Wood, M.D. 

Find more articles on women's heart issues in the Women's Cardiovascular Health channel 


Related Content

News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
News | Atrial Fibrillation

December 22, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home December 22, 2023
Home
News | Atrial Fibrillation

December 14, 2023 — Medtronic plc, a global leader in healthcare technology, today announced that the United States Food ...

Home December 14, 2023
Home
News | Atrial Fibrillation

December 13, 2023 — A new artificial intelligence (AI) model designed by Scripps Research scientists could help ...

Home December 13, 2023
Home
Subscribe Now